Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 10 of 10

Publication Record

Connections

Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors.
Grouthier V, Lebrun-Vignes B, Glazer AM, Touraine P, Funck-Brentano C, Pariente A, Courtillot C, Bachelot A, Roden DM, Moslehi JJ, Salem JE
(2018) Heart 104: 1859-1863
MeSH Terms: Action Potentials, Adolescent, Adult, Adverse Drug Reaction Reporting Systems, Aged, Aged, 80 and over, Aromatase Inhibitors, Cardiotoxicity, Databases, Factual, Europe, Female, Heart Conduction System, Heart Rate, Humans, Long QT Syndrome, Middle Aged, Prognosis, Risk Assessment, Risk Factors, Selective Estrogen Receptor Modulators, Tamoxifen, Torsades de Pointes, Young Adult
Added October 1, 2018
0 Communities
2 Members
0 Resources
23 MeSH Terms
A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.
Mayer IA, Abramson VG, Formisano L, Balko JM, Estrada MV, Sanders ME, Juric D, Solit D, Berger MF, Won HH, Li Y, Cantley LC, Winer E, Arteaga CL
(2017) Clin Cancer Res 23: 26-34
MeSH Terms: Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Aromatase Inhibitors, Biomarkers, Tumor, Breast Neoplasms, Cell Line, Tumor, DNA Mutational Analysis, Female, Humans, In Situ Hybridization, Fluorescence, Letrozole, Maximum Tolerated Dose, Middle Aged, Mutation, Neoplasm Metastasis, Neoplasm Staging, Nitriles, Phosphatidylinositol 3-Kinases, Phosphoinositide-3 Kinase Inhibitors, Receptor, ErbB-2, Receptor, Fibroblast Growth Factor, Type 1, Receptors, Estrogen, Thiazoles, Treatment Outcome, Triazoles
Added April 6, 2017
0 Communities
1 Members
0 Resources
26 MeSH Terms
Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer.
Ciruelos E, Cortes-Funes H, Ghanem I, Manso L, Arteaga C
(2013) Anticancer Drugs 24: 769-80
MeSH Terms: Androstadienes, Animals, Antineoplastic Combined Chemotherapy Protocols, Aromatase Inhibitors, Biomarkers, Tumor, Breast Neoplasms, Disease-Free Survival, Everolimus, Female, Humans, Molecular Targeted Therapy, Protein Kinase Inhibitors, Signal Transduction, Sirolimus, TOR Serine-Threonine Kinases, Treatment Outcome
Show Abstract · Added March 7, 2014
Approximately 75% of patients with breast cancer present hormone receptor-positive tumors. This subtype of breast cancer initially shows a high overall response rate to hormonal treatments. However, resistance eventually develops, resulting in tumor progression. The PI3K/Akt/mTOR pathway regulates several cellular functions in cancer such as cell growth, survival, and proliferation. In addition, a high activation level of the PI3K/Akt/mTOR pathway is related to resistance to conventional chemotherapy and hormone therapy. The mTOR inhibitor everolimus, in combination with hormonal treatments, has led to excellent results in progression-free survival in patients with metastatic breast cancer resistant to hormone therapies. Therefore, everolimus has entered the National Comprehensive Cancer Network (NCCN) guidelines 2012 and its combination with exemestane was approved recently by the US Food and Drug Administration and the European Medicines Agency. This is the first time that a drug will have been approved for the restoration of hormone sensitivity in breast cancer.
0 Communities
1 Members
0 Resources
16 MeSH Terms
Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis.
Brown NJ
(2013) Nat Rev Nephrol 9: 459-69
MeSH Terms: Aldosterone, Animals, Aromatase Inhibitors, Cardiovascular System, Cytochrome P-450 CYP11B2, Endothelial Cells, Fadrozole, Fibrosis, Humans, Imidazoles, Inflammation, Kidney, Macrophages, Mineralocorticoid Receptor Antagonists, Myocardium, Myocytes, Cardiac, Pyridines, Reactive Oxygen Species, Receptors, Mineralocorticoid, Sodium, Dietary
Added December 10, 2013
0 Communities
1 Members
0 Resources
20 MeSH Terms
Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort.
Castel LD, Hartmann KE, Mayer IA, Saville BR, Alvarez J, Boomershine CS, Abramson VG, Chakravarthy AB, Friedman DL, Cella DF
(2013) Cancer 119: 2375-82
MeSH Terms: Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Hormonal, Aromatase Inhibitors, Arthralgia, Breast Neoplasms, Female, Follow-Up Studies, Humans, Middle Aged, Multivariate Analysis, Poisson Distribution, Postmenopause, Prospective Studies, Risk Factors
Added March 5, 2014
0 Communities
5 Members
0 Resources
16 MeSH Terms
Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification.
Balko JM, Mayer IA, Sanders ME, Miller TW, Kuba MG, Meszoely IM, Wagle N, Garraway LA, Arteaga CL
(2012) Mol Cancer Ther 11: 2301-5
MeSH Terms: Aromatase Inhibitors, Base Sequence, Breast Neoplasms, Drug Resistance, Neoplasm, Female, Gene Amplification, Humans, Letrozole, Middle Aged, Molecular Sequence Data, Mutation, Nitriles, Proto-Oncogene Proteins, Proto-Oncogene Proteins p21(ras), Receptor, Fibroblast Growth Factor, Type 1, Receptors, Estrogen, Triazoles, ras Proteins
Added September 3, 2013
0 Communities
6 Members
0 Resources
18 MeSH Terms
Breast cancer. Clinical practice guidelines in oncology.
Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, Wolff AC, NCCN Breast Cancer Clinical Practice Guidelines Panel
(2009) J Natl Compr Canc Netw 7: 122-92
MeSH Terms: Algorithms, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Aromatase Inhibitors, Breast, Breast Neoplasms, Combined Modality Therapy, Female, Humans, Lymphatic Metastasis, Mastectomy, Neoadjuvant Therapy, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Neoplasm Staging, Neoplasms, Hormone-Dependent, Postmenopause, Premenopause, Randomized Controlled Trials as Topic, Receptor, ErbB-2, Selective Estrogen Receptor Modulators, Sentinel Lymph Node Biopsy, Tamoxifen, Trastuzumab
Added March 5, 2014
0 Communities
1 Members
0 Resources
24 MeSH Terms
Structural biology: Anticancer drug target pictured.
Waterman MR
(2009) Nature 457: 159-60
MeSH Terms: Aromatase, Aromatase Inhibitors, Breast Neoplasms, Catalytic Domain, Crystallography, X-Ray, Estrogens, Female, Humans
Added February 12, 2015
0 Communities
1 Members
0 Resources
8 MeSH Terms
ErbB receptor signaling and therapeutic resistance to aromatase inhibitors.
Shin I, Miller T, Arteaga CL
(2006) Clin Cancer Res 12: 1008s-1012s
MeSH Terms: Acetyltransferases, Androstenedione, Aromatase Inhibitors, Breast Neoplasms, Carrier Proteins, Cell Line, Tumor, Corticosterone, Drug Resistance, Neoplasm, Female, Histone Acetyltransferases, Humans, Letrozole, Nitriles, Nuclear Receptor Coactivator 3, Oncogene Proteins, Promoter Regions, Genetic, Receptor, ErbB-2, Receptors, Estrogen, Signal Transduction, Trans-Activators, Transcriptional Activation, Triazoles
Added March 5, 2014
0 Communities
1 Members
0 Resources
22 MeSH Terms
Characterization of stable human aromatase expressed in E. coli.
Kagawa N, Hori H, Waterman MR, Yoshioka S
(2004) Steroids 69: 235-43
MeSH Terms: Amino Acid Sequence, Androstenedione, Arginine, Aromatase, Aromatase Inhibitors, Cell Membrane, Chaperonin 10, Chaperonin 60, Chloramphenicol, Cysteine, Electron Spin Resonance Spectroscopy, Enzyme Stability, Escherichia coli, Estradiol, Estrone, Fadrozole, Gene Expression, Humans, Letrozole, Molecular Sequence Data, Nitriles, Polymorphism, Genetic, Protein Structure, Secondary, Protein Synthesis Inhibitors, Recombinant Proteins, Solubility, Testosterone, Triazoles
Added February 12, 2015
0 Communities
1 Members
0 Resources
28 MeSH Terms